KLRC1 and squamous cell carcinoma: The monoclonal antibody monalizumab, which binds and neutralizes the inhibitory NK receptor, NKG2A, produced robust cytotoxicity against NKG2A ligand-expressing tumor cells and against an antibody-coated squamous cell carcinoma of the head and neck (SCCHN) cell line [92].